

JUL 26 1999

K992244

I. 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS

Greiner Meditech, Inc. („Greiner“) is submitting a 510(k) pre-market notification for its Greiner MiniCollect® Coagulation tube with 3.2% sodium citrate solution for venous blood collection. The Greiner MiniCollect® is a non-sterile, non-evacuated blood collection device containing a 3.2% sodium citrate solution, intended to collect, transport, and process whole blood for coagulation testing.

Greiner is claiming substantial equivalence to it's VACUETTE® Coagulation tube (K971221). Both blood collection tubes have the same intended use and are made out of plastic. The equivalence of assay results for both tubes was evaluated by testing paired samples collected in Greiner MiniCollect® Coagulation tubes and Greiner VACUETTE® Coagulation tubes.

Greiner's 510(k) has been submitted on July 1, 1999 by Doug Harris, Managing Director, Greiner Meditech, Inc., 260 Gateway Drive, Suite 17A, Bel Air, MD 21014 (410/836-8228).



DEPARTMENT OF HEALTH & HUMAN SERVICES

JUL 26 1999

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Mr. Douglas L. Harris
Managing Director
Greiner Meditech, Inc.
P.O. Box 943
Bel Air, Maryland 21014

Re: K992244
Trade Name: MiniCollect® Coagulation Blood Collection Tube
Regulatory Class: II
Product Code: JKA
Dated: July 2, 1999
Received: July 2, 1999

Dear Mr. Harris:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.


Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D, M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure



VACUETTE®
North America



To: Alan Peacock	From: Douglas L Harris
Fax: [Click here and type fax number]	Pages: [Click here and type # of pages]
Phone: [Click here and type phone number]	Date: 07/13/99
Re: Coag 510k responses	CC: Helene Restrepo

Urgent For Review Please Comment Please Reply Please Recycle

Alan our 510 number for the VACUETTE® \Coag tube is

Indications for use

The MiniCollect® Coagulation tube is intended for collection of citrate anticoagulated whole blood samples for Coagulation Assays.

 (Division Sign-Off)
 Division of Clinical Laboratory Devices
 510(k) Number K 992244

 Concurrence of CDREH, Office of Device Evaluation (ODE)

Prescription Use ✓
 per 21 CFR 801.109